MSCs-based therapies have broad application potential in reducing ischemia/reperfusion injury, but their use for treating isolated organs before transplantation remains limited. Here, the authors present a new technology, which enables to better exploit the benefits of cell-based therapies during NMP.
- Umberto Cillo
- Caterina Lonati
- Daniele Dondossola
